Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
Acute lymphoblastic leukemia
BFM-95
children
minimal residual disease
relapse
Journal
Pediatric hematology and oncology
ISSN: 1521-0669
Titre abrégé: Pediatr Hematol Oncol
Pays: England
ID NLM: 8700164
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
14
8
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Prognostic predictive value of end of induction minimal residual disease (EOI-MRD) is well established in acute lymphoblastic leukemia (ALL). We evaluated the factors likely to affect EOI-MRD positivity (>0.01%) by flow cytometry and relapse in different BFM-95 (Berlin-Frankfurt-Munich) risk groups among children and adolescents. In this retrospective study, data of 223 newly diagnosed patients with ALL was analyzed. Association between demographic and pretreatment characteristics with EOI-MRD was assessed. Risk factors for relapse were analyzed using univariate and multivariate Cox regression. Proportion of the SR (standard risk), MR (moderate risk), and HR (high risk) patients was 18.8%, 60.9%, 20.3%, respectively. Positive EOI-MRD among these risk groups was observed in 11.9%, 18.3%, and 55.5% patients respectively (
Identifiants
pubmed: 36930957
doi: 10.1080/08880018.2023.2186553
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM